Rajkot-based Anlon Healthcare Limited reported a sharp rise in its consolidated financial performance for the quarter ended June 30, 2026, with total income climbing 163.02% year-on-year, driven partly by its recent acquisition in the Finished Dosage Formulations (FDF) segment.
Topline, EBITDA and PAT all more than double
For Q1FY27, Anlon Healthcare’s consolidated total income rose to ₹87.62 crore from ₹33.31 crore in the same quarter last year. EBITDA grew 150.14% to ₹15.65 crore from ₹6.26 crore, while profit after tax rose 133.13% to ₹8.28 crore from ₹3.55 crore in Q1FY26.
Acquisition marks entry into formulations
A key development during the quarter was the acquisition of a 63.98% stake in Remember India Health Links Pvt. Ltd. for a consideration of ₹5.38 crore, with the deal completed on May 8, 2026, making the target company a subsidiary of Anlon Healthcare.
The move gives Anlon access to more than 30 formulation dossiers and marks its entry into the FDF segment, complementing its existing API business. The company said this also expands its footprint across B2B APIs, domestic retail and hospital markets.
Anlon Healthcare manufactures high-purity pharmaceutical intermediates and APIs, including Loxoprofen Sodium Dihydrate, Ketoprofen and Dexketoprofen Trometamol, serving pharmaceutical, nutraceutical, personal care and animal health industries across 15+ countries.
Chairman and Managing Director Punitkumar Rasadia attributed the quarter’s performance to the company’s diversified pharmaceutical portfolio and its recent acquisitions. He said the results reflect “the strength of our diversified pharmaceutical portfolio, continued customer confidence and the positive contribution from our strategic acquisitions,” and added that the company’s margins point to “the resilience of our business model.”
The company has an installed capacity of 1,400-1,600 MTPA and four R&D centres.
On the Remember India Health Links deal, Rasadia said it marks the company’s “strategic entry into the Finished Dosage Formulations (FDF) segment,” and that together with its Apiqo Organics and Bizotic Lifescience investments, these moves “significantly enhance our manufacturing capabilities” across the pharmaceutical value chain.
Looking ahead, the company reiterated long-term guidance of approximately 30% revenue CAGR over the next three years, while maintaining EBITDA margins in the range of 25-30%, as it focuses on expanding in regulated markets and scaling its CDMO business.
